(Q37908142)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21801084%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

review article

1 reference

title

The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21801084%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

Pier Francesco Ferrucci

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21801084%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Alessandro Testori

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21801084%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Alessandra di Pietro

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21801084%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Giulio Tosti

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21801084%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

language of work or name

English

0 references

publication date

30 July 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21801084%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

9 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21801084%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21801084%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21801084%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

1395-1407

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21801084%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Melanoma immunology: past, present and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Cancer/testis (CT) antigens: potential targets for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Vaccine therapy for melanoma: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

A molecular perspective of CTLA-4 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Phase I/II study of ipilimumab for patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Advances in systemic treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Immunotherapy for advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Heat-shock proteins as powerful weapons in vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Immunotherapy for melanoma: current status and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Guidelines for the nomenclature of the human heat shock proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Heat shock protein-based cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Immunotherapy for human cancer using heat shock protein-peptide complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Essential role of CD91 in re-presentation of gp96-chaperoned peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Heat shock proteins gp96 and hsp70 activate the release of nitric oxide by APCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Immunization with chaperone-peptide complex induces low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Immunologic functions as prognostic indicators in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Immunotherapy of human cancer: lessons from mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Erlotinib and bevacizumab have synergistic activity against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605353

10.1517/14712598.2011.605353

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21801084%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference